Equity Overview
Price & Market Data
Price: $2.59
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $284,159,264
Volume: 0
Performance Metrics
1 Week: 22.17%
1 Month: 52.35%
3 Months: -0.77%
6 Months: -49.81%
1 Year: -61.86%
YTD: -49.51%
Company Details
Employees: 100
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.